Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 2/20 | 0.50 |
| ▸ | LDHB | P07195 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | FNTA | P49354 | 1/20 | 0.31 |
| ▸ | FNTB | P49356 | 1/20 | 0.31 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL343159 | 1.00 | LDHA (0.50) | LDHALDHBLMNABLMALOX15 | |
| SCHEMBL2999475 | 1.00 | LDHA (0.50) | LDHALDHBLMNABLMALOX15 | |
| SCHEMBL27696587 | 0.86 | LMNA (0.58) | LDHALDHBLMNABLMALOX15 | |
| SCHEMBL4141273 | 0.86 | LMNA (0.58) | LDHALDHBLMNABLMALOX15 | |
| SCHEMBL4779556 | 0.86 | LMNA (0.58) | LDHALDHBLMNABLMALOX15 | |
| SCHEMBL27476647 | 0.82 | LMNA (0.54) | LDHALDHBLMNABLMALOX15 | |
| SCHEMBL105998 | 0.82 | FFAR3 (0.55) | LDHALDHBLMNABLMALOX15 | |
| SCHEMBL10661655 | 0.82 | FFAR3 (0.55) | LDHALDHBLMNABLMALOX15 | |
| SCHEMBL141678 | 0.82 | FFAR3 (0.55) | LDHALDHBLMNABLMALOX15 | |
| SCHEMBL10661623 | 0.82 | FFAR3 (0.55) | LDHALDHBLMNABLMALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12543952-B2 | Imaging system and method for fluorescence guided surgery | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2026-02-10 | — | — | US | disclosed |
| US-20240148912-A1 | Activatable Membrane-Interacting Peptides and Methods of Use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-05-09 | — | — | US | disclosed |
| US-11712483-B2 | Activatable membrane-interacting peptides and methods of use | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-20220175955-A1 | PEPTIDE DISPLAY TO ANTIGEN PRESENTING CELLS USING LIPID VEHICLE | DANMARKS TEKNISKE UNIVERSITET (DK) | 2022-06-09 | — | — | US | disclosed |
| US-20220008526-A1 | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY | TORQUE THERAPEUTICS, INC. | 2022-01-13 | — | — | US | disclosed |
| EP-3880232-A1 | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY | Torque Therapeutics, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| EP-3794019-A1 | PEPTIDE DISPLAY TO ANTIGEN PRESENTING CELLS USING LIPID VEHICLE | Torque Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| US-20200330514-A1 | Immunostimulatory Fusion Molecules and Uses Thereof | TORQUE THERAPEUTICS, INC. | 2020-10-22 | — | — | US | disclosed |
| US-20200306301-A1 | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof | TORQUE THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-20030224055-A1 | Compositions and processes for inhibiting gene expression using polynucleotides | ROCHE MADISON INC. | 2003-12-04 | — | — | US | disclosed |
| WO-2003099228-A2 | COMPOSITIONS AND PROCESSES FOR INHIBITING GENE EXPRESSION USING POLYNUCLEOTIDES | MIRUS CORPORATION (US) | 2003-12-04 | — | — | WO | disclosed |
| US-20030220264-A1 | Reversible modification of membrane interaction | ROZEMA DAVID B (US) | 2003-11-27 | — | — | US | disclosed |
| US-20030199090-A1 | Compositions and methods for drug delivery using pH sensitive molecules | Arrowhead Pharmaceuticals, Inc. | 2003-10-23 | — | — | US | disclosed |
| US-6630351-B1 | Transfecting a cell by attaching a reversible labile membrane activity inhibitor to a melittin peptide; adding peptide to solution containing the nucleic acid; endocytosis | MIRUS CORPORATION | 2003-10-07 | — | — | US | disclosed |
| US-20030026841-A1 | Compositions and methods for drug delivery using pH sensitive molecules | Arrowhead Madison Inc. | 2003-02-06 | — | — | US | disclosed |
| EP-1246532-A2 | DELIVERY OF SINGLE STRANDED DNA FOR EXPRESSION | Mirus Corporation (US) | 2002-10-09 | — | — | EP | disclosed |
| EP-1102785-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES | Mirus Corporation (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000075164-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES | MIRUS CORPORATION (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000074635-A2 | DELIVERY OF SINGLE STRANDED DNA FOR EXPRESSION | MIRUS CORPORATION (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11712483-B2 | Activatable membrane-interacting peptides and methods of use | ANXA5, PLA2G2A, F13B | LDHA 4089/4885LDHB 3383/4885LMNA 108/4885 |
| US-20240148912-A1 | Activatable Membrane-Interacting Peptides and Methods of Use | ANXA5, F13B, PLA2G2A | LDHA 4069/4885LDHB 3329/4885LMNA 112/4885 |
| US-12543952-B2 | Imaging system and method for fluorescence guided surgery | FAU, ZKSCAN2, IWS1 | LDHA 3675/4885LDHB 3756/4885LMNA 2436/4885 |
| US-20220008526-A1 | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY | ICOS, CD274, TP53 | LDHA 1908/4885LDHB 1444/4885LMNA 3226/4885 |
| US-20030026841-A1 | Compositions and methods for drug delivery using pH sensitive molecules | POLI, POLN, POLRMT | LDHA 1265/4885LDHB 1438/4885LMNA 48/4885 |
| US-20200306301-A1 | Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof | IFNG, TLR3, IL2 | LDHA 3437/4885LDHB 2745/4885LMNA 3888/4885 |
| US-20220175955-A1 | PEPTIDE DISPLAY TO ANTIGEN PRESENTING CELLS USING LIPID VEHICLE | CD74, MICA, TAP1 | LDHA 3484/4885LDHB 2570/4885LMNA 3463/4885 |
| US-20200330514-A1 | Immunostimulatory Fusion Molecules and Uses Thereof | IL2, ICOS, IFNG | LDHA 3127/4885LDHB 2075/4885LMNA 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.